Trial Profile
APIDULCIS: Extended Anticoagulation With Low-dose Apixaban After a Standard Course Anticoagulation in Patients With a First Venous Thromboembolism Who Have Positive D-dimer
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms APIDULCIS
- 01 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 10 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2021 Planned primary completion date changed from 1 Feb 2021 to 30 Oct 2021.